共 50 条
- [32] HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 763 - 763Kavanaugh, A.Lubrano, E.Muram, T.Lin, C. Y.Leage, S. LiuVan den Bosch, F.Kristensen, L. E.
- [33] No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical TrialsAMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (08): : 1197 - 1205Singh, SiddharthProudfoot, James A.Dulai, Parambir S.Jairath, VipulFumery, MathurinXu, RonghuiFeagan, Brian G.Sandborn, William J.
- [34] Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT IIAMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S449 - S449Danese, SilvioSandborn, William J.Reinisch, WalterHebuterne, XavierKlopocka, MariaTarabar, DinoVanasek, TomasGregus, MilosHellstern, Paul A.Kim, Joo SungSparrow, MilesGorelick, Kenneth J.Goetsch, MartinaBliss, CalebGupta, CharuCataldi, FabioVermeire, Severine
- [35] HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RAARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)Rigby, WilliamBuckner, Jane H.Bridges, S. Louis, Jr.Nys, MarleenGao, ShengPolinsky, MartinRay, NeelanjanaBykerk, Vivian
- [36] HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RAArthritis Research & Therapy, 23William RigbyJane H. BucknerS. Louis BridgesMarleen NysSheng GaoMartin PolinskyNeelanjana RayVivian Bykerk
- [37] Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head StudyARTHRITIS & RHEUMATOLOGY, 2020, 72McInnes, IainMease, PhilipGladman, DafnaCoates, LauraNash, PeterOgdie, AlexisBehrens, FrankGoupille, PhilippeKavanaugh, ArthurMartin, RuvieQuebe-Fehling, ErhardGaillez, Corine
- [38] IMPACT OF CONTINUING 5-AMINOSALICYLATES IN PATIENTS WITH ULCERATIVE COLITIS ESCALATED TO BIOLOGIC THERAPY: POOLED ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM INFLIXIMAB AND GOLIMUMAB CLINICAL TRIALSGASTROENTEROLOGY, 2018, 154 (06) : S111 - S111Singh, SiddharthProudfoot, JamesFumery, MathurinDulai, ParambirBoland, Brigid S.Xu, RonghuiSandborn, William J.
- [39] Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumabMEDICINE, 2020, 99 (19) : E20201Schmalzing, MarcBehrens, FrankSchwaneck, Eva C.Koehm, MichaelaGreger, GerdGnann, HolgerBurkhardt, HaraldTony, Hans-Peter
- [40] THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NAIVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED 'EARLY AMPLE' TRIALANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 291 - 291Rigby, W.Buckner, J.Bridges, S. L., Jr.Nys, M.Gao, S.Polinsky, M.Ray, N.Bykerk, V.